Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
307.4 USD | +0.00% | +3.71% | +6.72% |
Jun. 05 | Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints | MT |
Jun. 05 | Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.72% | 165B | |
+42.69% | 749B | |
+34.11% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+18.08% | 248B | |
-3.44% | 214B | |
+11.35% | 216B | |
+2.64% | 167B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen to Acquire Drugmaker ChemoCentryx in $3.7 Billion Deal